IS5087A - Stöðugar interferónlyfjablöndur á vökvaformi - Google Patents

Stöðugar interferónlyfjablöndur á vökvaformi

Info

Publication number
IS5087A
IS5087A IS5087A IS5087A IS5087A IS 5087 A IS5087 A IS 5087A IS 5087 A IS5087 A IS 5087A IS 5087 A IS5087 A IS 5087A IS 5087 A IS5087 A IS 5087A
Authority
IS
Iceland
Prior art keywords
liquid
interferon
compositions
beta
stable liquid
Prior art date
Application number
IS5087A
Other languages
English (en)
Other versions
IS2070B (is
Inventor
Mary D Dibiasi
Staples Mark
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IS5087A publication Critical patent/IS5087A/is
Publication of IS2070B publication Critical patent/IS2070B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5087A 1996-12-24 1999-06-21 Stöðugar interferónlyfjablöndur á vökvaformi IS2070B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (2)

Publication Number Publication Date
IS5087A true IS5087A (is) 1999-06-21
IS2070B IS2070B (is) 2005-12-15

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5087A IS2070B (is) 1996-12-24 1999-06-21 Stöðugar interferónlyfjablöndur á vökvaformi

Country Status (28)

Country Link
EP (1) EP0948358B2 (is)
JP (5) JP4878664B2 (is)
KR (2) KR20000069664A (is)
CN (2) CN1733296B (is)
AT (1) ATE270899T1 (is)
AU (1) AU738362B2 (is)
BG (2) BG65418B1 (is)
BR (1) BR9714434A (is)
CA (1) CA2275890C (is)
CZ (1) CZ300636B6 (is)
DE (1) DE69729880T3 (is)
DK (1) DK0948358T4 (is)
EA (1) EA002754B1 (is)
EE (2) EE04223B1 (is)
ES (1) ES2224290T5 (is)
HK (2) HK1025040A1 (is)
HU (1) HU224222B1 (is)
IL (1) IL130524A (is)
IS (1) IS2070B (is)
MX (1) MX337876B (is)
NO (1) NO327844B1 (is)
NZ (2) NZ336548A (is)
PL (1) PL193447B1 (is)
PT (1) PT948358E (is)
SI (1) SI0948358T2 (is)
SK (1) SK284989B6 (is)
TR (1) TR199901968T2 (is)
WO (1) WO1998028007A1 (is)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ATE270899T1 (de) * 1996-12-24 2004-07-15 Biogen Inc Stabile flüssige interferon-zubereitungen
CA2304808C (en) 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
CN100448482C (zh) * 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
WO2003061687A1 (en) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドの安定化された固体組成物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EP1628677B1 (en) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
BRPI0416042A (pt) * 2003-11-13 2007-01-02 Alza Corp composição e aparelho para suprimento transdérmico
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
PT2298287T (pt) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Composições estabilizadas de polipéptidos de fator vii
US7858082B2 (en) * 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
US20080193997A1 (en) * 2004-08-24 2008-08-14 Kenji Kangawa Liquid Preparation of Physiologically Active Peptide
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1809662B1 (en) * 2004-11-10 2008-11-26 Novartis Vaccines and Diagnostics, Inc. Deamidated interferon-beta
KR101238148B1 (ko) * 2005-01-12 2013-03-04 바이오겐 아이덱 엠에이 인코포레이티드 인터페론 베타의 전달 방법
AU2006206272A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
WO2007003936A1 (en) 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA3240562A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
PT2234645E (pt) 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2283027B2 (en) 2008-05-01 2018-04-18 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9452216B2 (en) 2010-12-09 2016-09-27 Maruishi Pharmaceutical Co., Ltd. Agent for stabilizing acetaminophen
LT2686002T (lt) 2011-03-15 2018-05-10 Biogen Ma Inc. Gripo tipo simptomų sumažinimo būdas, susijęs su interferono skyrimu į raumenis, naudojant greitą titravimą sukeliantį dozavimo rėžimą
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
MX2014012461A (es) * 2012-04-19 2015-01-12 Bard Inc C R Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程(集团)股份有限公司 一种重组人干扰素α2b制剂
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
MX2022013662A (es) * 2020-04-29 2023-02-01 Abion Inc Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
CA3242509A1 (en) * 2021-12-27 2023-07-06 Joseph V. Pergolizzi Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (is) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
JPH09511745A (ja) * 1994-04-08 1997-11-25 ブリガム アンド ウィミンズ ホスピタル 経口寛容および/またはタイプiインターフェロンを用いた自己免疫疾患の治療
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
ATE270899T1 (de) * 1996-12-24 2004-07-15 Biogen Inc Stabile flüssige interferon-zubereitungen

Also Published As

Publication number Publication date
IL130524A0 (en) 2000-06-01
ES2224290T3 (es) 2005-03-01
NZ336548A (en) 2001-09-28
ES2224290T5 (es) 2012-03-12
EE04223B1 (et) 2004-02-16
JP2007204501A (ja) 2007-08-16
CA2275890A1 (en) 1998-07-02
JP2001519770A (ja) 2001-10-23
EP0948358B2 (en) 2011-11-23
IS2070B (is) 2005-12-15
DE69729880D1 (de) 2004-08-19
DK0948358T4 (da) 2012-03-19
JP5851695B2 (ja) 2016-02-03
PL334365A1 (en) 2000-02-28
CZ228299A3 (cs) 1999-12-15
CN1733296B (zh) 2010-05-26
BG65171B1 (bg) 2007-05-31
SI0948358T2 (sl) 2012-03-30
JP2012006979A (ja) 2012-01-12
HUP0000829A3 (en) 2002-01-28
SI0948358T1 (en) 2005-04-30
CA2275890C (en) 2011-11-01
EA199900597A1 (ru) 2000-02-28
AU5619198A (en) 1998-07-17
MX337876B (es) 2016-03-22
EP0948358B1 (en) 2004-07-14
CN1245434A (zh) 2000-02-23
TR199901968T2 (xx) 1999-12-21
BG103594A (en) 2000-04-28
HU224222B1 (hu) 2005-06-28
BR9714434A (pt) 2000-05-02
CN1222315C (zh) 2005-10-12
JP2014098029A (ja) 2014-05-29
DE69729880T3 (de) 2012-05-10
AU738362B2 (en) 2001-09-13
HK1092048A1 (en) 2007-02-02
EE200300127A (et) 2003-06-16
ATE270899T1 (de) 2004-07-15
DE69729880T2 (de) 2005-07-07
SK85899A3 (en) 2000-01-18
EE04266B1 (et) 2004-04-15
PT948358E (pt) 2004-10-29
JP2011068694A (ja) 2011-04-07
EP0948358A1 (en) 1999-10-13
NO993121D0 (no) 1999-06-23
NO993121L (no) 1999-08-24
BG65418B1 (bg) 2008-07-31
EA002754B1 (ru) 2002-08-29
IL130524A (en) 2005-08-31
HK1025040A1 (en) 2000-11-03
SK284989B6 (sk) 2006-04-06
PL193447B1 (pl) 2007-02-28
KR20000069664A (ko) 2000-11-25
CN1733296A (zh) 2006-02-15
DK0948358T3 (da) 2004-11-08
NO327844B1 (no) 2009-10-05
BG109523A (en) 2007-05-31
JP4878664B2 (ja) 2012-02-15
KR20070052363A (ko) 2007-05-21
WO1998028007A1 (en) 1998-07-02
NZ512792A (en) 2002-11-26
KR101042660B1 (ko) 2011-06-20
CZ300636B6 (cs) 2009-07-08
HUP0000829A2 (en) 2000-07-28
EE9900313A (et) 2000-04-17

Similar Documents

Publication Publication Date Title
IS5087A (is) Stöðugar interferónlyfjablöndur á vökvaformi
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2032499A1 (en) Polypeptide derivatives
DE3166150D1 (en) N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
PL274485A1 (en) Method of obtaining stable preparations of human proteins
CA2094027A1 (en) Osteogenic peptides
AU1094892A (en) Improved activation of recombinant proteins
AU4009789A (en) Recombinant natural killer cell activator
AU678421B2 (en) Highly concentrated TCF pharmaceutical preparations
JPS51125790A (en) Carrier for fixing of biologically active substances
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
GB9604518D0 (en) Novel compounds
KR860003012A (ko) (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물